Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar^®) in older patients with essential hypertension: Subgroup analysis from the Sevikar study.

ABSTRACT: Essential hypertension is a notable threat for the older (age, ≥65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar^®) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean ± standard error chan

SUBMITTER: Cui Z 

PROVIDER: S-EPMC10790165 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature